2023
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Chu C, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Giuntoli R, Han E, Holmes J, Howitt B, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 181-209. PMID: 36791750, DOI: 10.6004/jnccn.2023.0006.Peer-Reviewed Original ResearchConceptsUterine neoplasmsNCCN guidelinesNCCN Clinical Practice GuidelinesPure endometrioid carcinomasUterine cancer casesClinical practice guidelinesFemale genital tractMesenchymal sarcomaEndometrial histologyEndometrioid cancerCommon malignancyEndometrial carcinomaUncommon subtypeEndometrioid carcinomaUterine cancerGenital tractCancer casesPractice guidelinesCarcinomaNeoplasmsCancerGuidelinesAdenocarcinomaEndometriumSarcoma
2020
Association Between Breastfeeding and Ovarian Cancer Risk
Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J, Goodman MT, Thompson PJ, Moysich KB, Ness RB, Kjaer SK, Jensen A, Schildkraut JM, Titus LJ, Cramer DW, Bandera EV, Qin B, Sieh W, McGuire V, Sutphen R, Pearce CL, Wu AH, Pike M, Webb PM, Modugno F, Terry KL. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology 2020, 6: e200421. PMID: 32239218, PMCID: PMC7118668, DOI: 10.1001/jamaoncol.2020.0421.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive ovarian cancerEpithelial ovarian cancerOvarian cancerCancer riskLower riskOdds ratioLogistic regressionHigh-grade serous subtypeHistotype-specific associationsMultivariable logistic regressionCase-control studyOvarian Cancer Association ConsortiumPolytomous logistic regressionParous womenEndometrioid cancerModifiable factorsPooled analysisSerous subtypeMAIN OUTCOMEBreastfeedingMore monthsOverall associationLethal typeCancer
2017
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data
Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim H, Sadowska J, Berger M, Delair D, Shia J, Stadler Z, Klimstra D, Ladanyi M, Zehir A, Hechtman J. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology 2017, 2017: 1-17. PMID: 30211344, PMCID: PMC6130812, DOI: 10.1200/po.17.00084.Peer-Reviewed Original ResearchPolymerase chain reactionMicrosatellite instability statusColorectal cancerMicrosatellite instabilityResponse to immune checkpoint inhibitorsMSI-HImmune checkpoint inhibitorsMMR immunohistochemistryAdvanced solid cancersManagement of patientsSolid cancer typesTargeted NGS dataCheckpoint inhibitorsClinical NGS assayEndometrioid cancerMutational burdenSolid cancersNGS assayMSI polymerase chain reactionCancer typesCancerMSI-H tumorsPan-CancerNGS dataChain reaction
1996
Differences in Risk Factors for Epithelial Ovarian Cancer by Histologic Type
Risch H, Marrett L, Jain M, Howe G. Differences in Risk Factors for Epithelial Ovarian Cancer by Histologic Type. American Journal Of Epidemiology 1996, 144: 363-372. PMID: 8712193, DOI: 10.1093/oxfordjournals.aje.a008937.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerMucinous tumorsNonmucinous tumorsOvarian cancerHistologic typeOdds ratioPrimary epithelial ovarian cancerUnconditional logistic regression methodsInvasive serous cancerMucinous ovarian tumorsOral contraceptive useFull-term pregnancyRisk factor associationsCase-control studyOral contraceptivesSerous cancerEndometrioid cancerNoncontraceptive estrogensFat intakeInvasive cancerOvarian tumorsRisk factorsEpithelial tumorsReproductive factorsContraceptive use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply